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Takotsubo (Stress) Cardiomyopathy
To the Editor: Templin et al. (Sept. 3 issue)1 
highlight the fact that takotsubo cardiomyopathy 
is associated with a substantial rate of adverse 
events. With this in mind, an important aspect 
that the authors do not discuss is the prevalence 
of dynamic left ventricular outflow tract obstruc-
tion (LVOTO). Dynamic LVOTO is a condition 
with a recognized association with takotsubo 
cardiomyopathy and has been reported in 10 to 
20% of patients in much smaller studies.2-4 This 
association is important because the coexistence 
of hemodynamically significant LVOTO and acute 
left ventricular systolic dysfunction poses a major 
therapeutic challenge, since the accepted man-
agement strategy for either condition alone (i.e., 
negative inotropy and increased afterload for 
LVOTO or positive inotropy and reduced after-
load for acute left ventricular dysfunction) is poten-
tially catastrophic in the other. Thus, it has been 
speculated that some patients with takotsubo 
cardiomyopathy and LVOTO may be best treated 
with early extracorporeal mechanical circulatory 
support.5 Do the authors have any data regarding 
the prevalence of LVOTO and its management? 
Given the unsurpassed wealth of data they have 
accrued on takotsubo cardiomyopathy, this would 
seem to be an excellent opportunity to more ac-
curately characterize a potentially devastating 
complication.
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To the Editor: In their article on clinical obser-
vations from the International Takotsubo Regis-
try, Templin et al. report 30-day mortality of 5.9% 
among patients with takotsubo cardiomyopathy. 
In addition, 12.2% of patients received catechol-
amine-based inotropes. These proportions are 
higher than those recently reported by the 
Swedish Health Care Registry on Heart Disease 
(SWEDEHEART) (4.1% and 5.6%, respectively),1 
and we think that the high short-term mortality 
could be partially explained by the liberal use of 
inotropes.
To date, no randomized clinical trial has in-
vestigated pharmacologic treatment strategies in 
patients with takotsubo cardiomyopathy. How-
ever, a large body of preclinical and clinical evi-
dence implicates catecholamines in the patho-
physiology, which supports the argument that 
inotropes should be contraindicated in patients 
with takotsubo cardiomyopathy.2-4 Templin et al. 
found that the rate of catecholamine treatment 
was considerably higher among men than among 
women (21.0% vs. 11.2%), which corresponded 
to a higher 30-day mortality among men than 
among women (12.2% vs. 5.2%). Thus, it would 
therefore be valuable if the authors could indi-
cate whether the use of catecholamines is an 
independent predictor of death (after appropri-
ate adjustment for cofounders) in their registry.
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To the Editor: Templin and colleagues report 
substantial long-term morbidity and mortality 
among patients with takotsubo cardiomyopathy. 
In their diagnosis of this condition according to 
Mayo Clinic criteria, they do not clarify how they 
ruled out myocarditis. Myocarditis may present 
with apical ballooning that mimics takotsubo 
cardiomyopathy.1 Indeed, the inclusion of pa-
tients with atypical forms, particularly the focal 
type, may have further increased the risk of enroll-
ing patients with myocarditis. Among patients 
who have left ventricular dysfunction, an increase 
in troponin levels, and normal coronary arteries, 
myocarditis cannot be reasonably ruled out with-
out endomyocardial biopsy or cardiac magnetic 
resonance imaging (MRI).2 Myocardial edema 
without delayed enhancement is a typical feature 
of takotsubo cardiomyopathy,3 which allows for 
distinction from myocarditis on MRI.
The possible inclusion of patients with myo-
carditis in the study could have substantially 
increased the event rate. Caforio and colleagues 
reported a 6-year rate of death or heart trans-
plantation of 27% among patients with biopsy-
proven myocarditis, with biventricular dysfunc-
tion at presentation and the presence of virus on 
genomic analysis of myocardium being the best 
predictors of an adverse outcome.4 Thus, the ex-
clusion of myocarditis is crucial to refining the 
patient population and assessing the prognosis 
of patients with takotsubo cardiomyopathy.
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The authors reply: In response to the com-
ments of Dalzell: LVOTO occurs in approximately 
20% of patients with takotsubo cardiomyopathy1 
and may also develop later during the acute 
phase. It can be precipitated by inotropes and 
poses a substantial risk to the patient. Therefore, 
careful evaluation for the presence of a pressure 
gradient during angiography should be per-
formed, as well as serial echocardiography to sys-
tematically rule out the development of LVOTO 
later during hospitalization.2 Unfortunately, this 
approach has been implemented by only few cen-
ters, and because of the mostly retrospective 
nature of our registry, we cannot provide data 
on the incidence and prognostic value of LVOTO. 
As outlined by Dalzell, the administration of ino-
tropes potentially increases the pressure gradient 
during LVOTO, which also holds true for intra-
aortic counterpulsation. Although prospective data 
on short-term management of takotsubo cardio-
myopathy are lacking, active left ventricular un-
loading by microaxial pumps3 appears to be 
 attractive to support left ventricular dysfunction 
and to reduce the pressure gradient at the same 
time in such patients.
Redfors and Omerovic emphasize the risk of 
catecholamines for treating takotsubo cardiomy-
opathy. In a multivariate analysis in our cohort, 
the use of catecholamines was a strong and in-
dependent predictor of in-hospital death (Fig. 1A). 
The risk of death associated with catecholamines 
was very high but did not differ according to sex 
(Fig. 1B and 1C), which suggests that other fac-
tors are responsible for the observed difference 
in mortality between men and women. Our retro-
spective analysis may have been influenced by 
selection bias and other factors. However, we 
agree that catecholamines of any nature should 
be administered with great caution, not only be-
cause of their potential role in the pathogenesis 
of takotsubo cardiomyopathy but also because of 
the risk of hemodynamic worsening (e.g., by the 
precipitation of LVOTO).
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Pieroni and Bolognese emphasize the need 
for ruling out myocarditis in the diagnosis of 
takotsubo cardiomyopathy. Indeed, since MRI 
was not broadly available at the beginning of our 
study, it was not possible to use MRI data in a 
meaningful fashion. Patients with focal takot-
subo cardiomyopathy in our study shared most 
features with other patients with this condition 
(e.g., age, sex, and triggers), making myocarditis 
unlikely. However, we agree that differentiation 
between focal takotsubo cardiomyopathy and 
myocarditis is challenging. Cardiac MRI is suf-
Figure 1. Use of Catecholamines and Risk of In-Hospital Death among Patients with Takotsubo Cardiomyopathy.
Panel A shows predictors of in-hospital death in patients with takotsubo cardiomyopathy, as determined by means 
of logistic regression in multivariate analysis. LVEF denotes left ventricular ejection fraction, QTc QT interval corrected 
for heart rate, and ULN upper limit of normal range. Panel B shows Kaplan–Meier estimates of rates of death among 
men and women, according to receipt of catecholamines, as calculated by means of the log-rank test. Panel C shows 
the relative risk of in-hospital death among men and women according to receipt of catecholamines, as determined 
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ficient to distinguish the acute coronary syn-
drome, takotsubo cardiomyopathy, and myocar-
ditis in most cases and adds valuable information, 
such as the presence of right ventricular involve-
ment and intraventricular thrombi.4 Thus, in ad-
dition to current diagnostic criteria, we recom-
mend the use of cardiac MRI in patients with 
suspected takotsubo cardiomyopathy.
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Acute Methotrexate-Induced Crystal Nephropathy
To the Editor: Acute renal failure occurs in 
approximately 2% of patients who receive high-
dose methotrexate for the treatment of a hema-
tologic cancer.1-3 Despite the frequency of acute 
renal failure and the occurrence of distinct 
urinary crystals in this context,4,5 the presence 
of these crystals in human tissues has not been 
clearly documented. Here, we describe crystals 
within the kidney tubules of a patient with 
methotrexate-induced nephropathy.
A 52-year-old man with an aggressive B-cell 
lymphoma was prescribed intravenous metho-
trexate (1.20 g per square meter of body-sur-
face area over a 1-hour period, followed by 0.24 
g per square meter over a 23-hour period) on 
day 10 of a regimen of CODOX-M (dexametha-
sone, cyclophosphamide, doxorubicin, vincris-
tine, rituximab, cytarabine, methotrexate, and 
leucovorin). The creatinine concentration in 
serum was below 50 µmol per liter (0.57 mg 
per deciliter) before the infusion, but it in-
creased to 116 µmol per liter (1.31 mg per 
deciliter) approximately 20 hours after the in-
fusion and reached 465 µmol per liter (5.26 mg 
per deciliter) 4 days later (Fig. 1A). A small 
number of methotrexate-like crystals were also 
observed in the patient’s urine (Fig. 1B and 1C) 
in the absence of risk factors for drug-induced 
precipitation or other causes of crystal ne-
phropathy.
Examination of a renal-biopsy specimen ob-
tained 7 days after the infusion revealed severe 
acute tubular injury with numerous intratubu-
lar and interstitial deposits of unique appear-
ance (Fig. 1D–1J). These deposits were made up 
of compact or needle-shaped golden crystals 
arranged in annular structures (Fig. 1D and 
1E); they were positive on methenamine silver 
staining (Fig. 1H) and displayed blue or gold 
birefringence under polarized light (Fig. 1F and 
1G). Von Kossa and alizarin red stains were 
negative, the glomeruli appeared normal, and 
scarring was minimal (not shown).
Our findings indicate that intratubular crys-
tal formation does occur in humans during the 
course of methotrexate-induced acute renal fail-
ure (this has previously been suspected in non-
human primates; see the Supplementary Appen-
dix, available with the full text of this letter at 
NEJM.org) and document the morphologic fea-
tures of methotrexate-induced crystal nephropa-
thy. In this regard, certain types of urinary 
crystals are known to form or to undergo struc-
tural modifications in the bladder or after mic-
turition because of changes in pH, temperature, 
or bacterial activity.
This case also shows that acute renal failure 
can occur even in the absence of toxic metho-
trexate levels in plasma 24 to 48 hours after in-
fusion (Fig. 1A). For this reason, and because 
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